APPL2 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional disruption of the APPL2 gene in the human Jurkat T lymphocyte line. This loss-of-function model leverages a heterogeneous pool of edited alleles to achieve population-level target-gene disruption, enabling robust investigation of APPL2-mediated signaling without single-cell clonal isolation. The polyclonal format provides a practical and cost-effective tool for high-throughput functional genomics, drug target validation, and pathway dissection in a well-defined immune cell context.
The Jurkat cell line is an immortalized human CD4+ T lymphocyte model originally derived from acute T cell leukemia. Jurkat cells are extensively employed in biomedical research to study T cell receptor (TCR) signaling, apoptosis, and immune response mechanisms due to their well-characterized signaling cascades and ease of genetic manipulation. This cellular background is particularly suitable for examining how adaptor proteins like APPL2 influence lymphocyte activation, survival, and metabolic adaptation in a controlled and reproducible system.
APPL2 encodes a multifunctional adaptor protein that scaffolds critical interactions between phosphoinositides and numerous signaling molecules. It operates downstream of receptors such as INSR, IGF-1R, TLR4, and CD40, and directly interacts with APPL1, Rab5, Akt, and PI3K to coordinate insulin signaling and PI3K/Akt pathway activation. APPL2 further modulates downstream effectors including GSK3??, NF-??B, Cyclin D1, and mTOR, thereby integrating growth factor signals with endocytic trafficking and cytoskeletal dynamics to regulate cell proliferation, survival, and metabolism.
In the Jurkat T cell environment, APPL2 knockout disrupts key nodes where insulin and growth factor signaling intersect with TCR-mediated pathways. Loss of APPL2 alters the spatiotemporal regulation of Akt phosphorylation, NF-??B activation, and endosomal trafficking, providing a powerful model to dissect the scaffolding role of APPL2 in immune cell function. This disruption can affect downstream survival signals and metabolic reprogramming, making the knockout cells highly relevant for studies on T cell anergy, activation, and metabolic disease intersections.
APPL2 knockout Jurkat polyclonal cells are well-suited for a range of downstream assays, including Western blotting for APPL2 and phospho?Akt, RT?qPCR for APPL2 mRNA quantification, flow cytometry for apoptosis (Annexin V staining) and phospho?Akt levels, co?immunoprecipitation to assess PI3K interactions, T cell activation assays, and colony formation studies. These tools support research applications spanning insulin signaling, T cell receptor signaling, apoptosis, metabolic regulation, and CRISPR knockout functional validation. For technical inquiries or custom knockout requests, please contact Ascent Research.
